Olema Pharmaceuticals, Inc. (OLMA)
Olema Pharmaceuticals, Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in San Francisco, CA, US. The stock last traded at $10.54, up 1.05% on the session, giving a market capitalisation of $920.6M. On trailing twelve-month figures it carries a trailing P/E of -4.97, a net margin of 0.0%. Its beta of 2.01 implies it has historically moved more than the broad market.
Olema Pharmaceuticals, Inc., a biopharmaceutical enterprise in the clinical development stage, is dedicated to discovering, advancing, and commercializing therapeutic solutions for women's oncology. Headquartered in San Francisco, California, the company was established in 2006 and rebranded from CombiThera, Inc. in March 2009. Its most promising investigational compound, OP-1250, an estrogen receptor (ER) antagonist and selective ER degrader, is presently undergoing Phase 1/2 clinical evaluations. This drug candidate is being assessed for its efficacy in managing recurrent, locally advanced, or metastatic breast cancer that expresses estrogen receptors but is negative for human epidermal growth factor receptor 2.
Olema Pharmaceuticals, Inc. is most often compared with the following Healthcare names: